Literature DB >> 17425687

Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.

D J Quinlan1, J W Eikelboom, O E Dahl, B I Eriksson, P S Sidhu, J Hirsh.   

Abstract

BACKGROUND: Venography is commonly used to compare the efficacy of different thromboprophylaxis strategies for preventing deep vein thrombosis (DVT) in patients undergoing total hip replacement (THR) or total knee replacement (TKR).
METHODS: We explored the relation between asymptomatic DVT and symptomatic venous thromboembolism (VTE) in patients undergoing THR or TKR treated with standard doses of enoxaparin (30 mg b.i.d. or 40 mg o.d.) by comparing the incidence of asymptomatic DVT in venographic studies with the incidence of symptomatic VTE in studies where venography was not performed.
RESULTS: In 10 venographic studies involving 5796 patients, the incidence of asymptomatic DVT after THR was 13.2% [95% CI, 12.2-14.2%] and after TKR was 38.1% (95% CI, 35.5-40.8%). In two studies involving 3500 patients who did not undergo venography, the 90-day incidence of symptomatic VTE after THR was 2.7% (95% CI, 2.1-3.4%) and after TKR was 1.8% (95% CI, 0.9-2.7%). For every symptomatic VTE in THR studies where venography was not performed there were five asymptomatic DVTs in the venographic studies; for TKR, the ratio was 1:21. The incidence of asymptomatic DVT and the symptomatic VTE/asymptomatic DVT ratio was influenced by the venogram reading committee (Gothenburg vs. Hamilton: total DVT after THR, 19.5% vs. 8.7%, P < 0.0001; for TKR, 42.7% vs. 27.2%, P < 0.0001).
CONCLUSIONS: Comparisons across trials show a consistent relation between asymptomatic venographic DVT in patients undergoing elective THR or TKR surgery and symptomatic VTE in patients not undergoing venography. Differences exist in the strength of the relation depending on the type of surgery and the venogram reading committee.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425687     DOI: 10.1111/j.1538-7836.2007.02571.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

1.  Prevention of venous thromboembolism according to the guidelines of a domestic manual.

Authors:  Toshihiro Kaneko; Hideo Wada; Tsutomu Nobori; Norikazu Yamada; Mashio Nakamura; Masaaki Ito
Journal:  Int J Hematol       Date:  2010-05-21       Impact factor: 2.490

Review 2.  Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; John W Eikelboom; Michael K Gould; David A Garcia; Mark Crowther; M Hassan Murad; Susan R Kahn; Yngve Falck-Ytter; Charles W Francis; Maarten G Lansberg; Elie A Akl; Jack Hirsh
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Cut-off values of D-dimer and soluble fibrin for prediction of deep vein thrombosis after orthopaedic surgery.

Authors:  Akihiro Sudo; Hideo Wada; Tsutomu Nobori; Norikazu Yamada; Masaaki Ito; Rui Niimi; Masahiro Hasegawa; Koji Suzuki; Atsumasa Uchida
Journal:  Int J Hematol       Date:  2009-05-09       Impact factor: 2.490

Review 4.  A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal.

Authors:  Noel C Chan; Deborah Siegal; Mandy N Lauw; Jeffrey S Ginsberg; John W Eikelboom; Gordon H Guyatt; Jack Hirsh
Journal:  J Thromb Thrombolysis       Date:  2015-08       Impact factor: 2.300

5.  Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Authors:  Aurea Duran; Nishan Sengupta; Alexander Diamantopoulos; Fiona Forster; Louis Kwong; Michael Lees
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

Review 6.  Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.

Authors:  Vladimir Trkulja; Robert Kolundzic
Journal:  Croat Med J       Date:  2010-04       Impact factor: 1.351

Review 7.  A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

Authors:  Sam Schulman; Ammar Majeed
Journal:  Drug Saf       Date:  2011-06-01       Impact factor: 5.606

Review 8.  Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Authors:  Alok Kapoor; Warren Chuang; Nila Radhakrishnan; Kenneth J Smith; Dan Berlowitz; Jodi B Segal; Jeffrey N Katz; Elena Losina
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

9.  Venous Thromboembolism Risk Assessment and Thromboprophylaxis Practice in General Medical Patients Requiring Admissions to General Wards: A Singapore's Perspective.

Authors:  Chaozer Er; Navin Kuthiah; Thofique Adamjee; Jam Chin Tay
Journal:  Int J Angiol       Date:  2021-05-11

10.  Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty.

Authors:  Sylvie Plante; Etienne L Belzile; Dominique Fréchette; Jean Lefebvre
Journal:  Can J Surg       Date:  2017-02       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.